These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21081784)

  • 1. Complications of radioactive iodine treatment of thyroid carcinoma.
    Lee SL
    J Natl Compr Canc Netw; 2010 Nov; 8(11):1277-86; quiz 1287. PubMed ID: 21081784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
    Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
    Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial.
    Amini S; Golshani M; Moslehi M; Hajiahmadi S; Askari G; Iraj B; Bagherniya M
    Trials; 2023 Aug; 24(1):501. PubMed ID: 37550760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioactive iodine: An unappreciated threat to salivary gland function.
    Sunavala-Dossabhoy G
    Oral Dis; 2018 Mar; 24(1-2):198-201. PubMed ID: 29480611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
    Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
    Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiated thyroid cancer and selenium supplements for protection of salivary glands from
    Mazokopakis E
    Hell J Nucl Med; 2018; 21(1):83-84. PubMed ID: 29550852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
    Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
    Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.
    Savage MW; Sobel RK; Hoffman HT; Carter KD; Finkelstein MW; Shriver EM
    Ophthalmic Plast Reconstr Surg; 2015; 31(3):e50-2. PubMed ID: 24836449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
    Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
    Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.
    Zhang Y; Liang J; Li H; Cong H; Lin Y
    Nucl Med Commun; 2016 Feb; 37(2):110-5. PubMed ID: 26513055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.
    Diamond-Rossi SA; Jonklaas J; Jensen RE; Kuo C; Stearns S; Esposito G; Davidson BJ; Luta G; Bloom G; Graves KD
    J Cancer Surviv; 2020 Dec; 14(6):847-857. PubMed ID: 32506220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
    Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
    Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary gland dysfunction following radioactive iodine therapy.
    Wiesenfeld D; Webster G; Cameron F; Ferguson MM; MacFadyen EE; MacFarlane TW
    Oral Surg Oral Med Oral Pathol; 1983 Feb; 55(2):138-41. PubMed ID: 6572864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial for the use of thymus honey in decreasing salivary gland damage following radioiodine therapy for thyroid cancer: research protocol.
    Charalambous A; Frangos S; Talias M
    J Adv Nurs; 2014 Jul; 70(7):1663-71. PubMed ID: 24256334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up.
    Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH
    Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Parotid and Submandibular Glands With Shear Wave Elastography Following Radioactive Iodine Therapy for Papillary Thyroid Carcinoma.
    Rahatli FK; Turnaoglu H; Iyidir OT; Kirnap NG; Haberal KM; Aydın E; Uslu N
    J Ultrasound Med; 2019 Feb; 38(2):357-362. PubMed ID: 30027680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
    Mei X; Yao X; Feng F; Cheng W; Wang H
    BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.